Heart Failure

A new-user comparator study of adults with type 2 diabetes indicates use of SGLT2 inhibitors was associated with a 54% lower risk of hospitalizations for heart failure and a 15% lower risk of a modified MACE outcome compared to use of DPP-4 inhibitors.

An analysis of data from the Rochester Epidemiology Project suggests those with breast cancer or lymphoma who received treatment with anthracycline therapy experienced a more than doubling in risk of heart failure compared to controls without cancer.

Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.

Using data from more than 2 million US adults with nonsurgical hospitalizations, a new study from the Mayo Clinic is sounding the alarm on the increased cardiovascular risk associated with developing sepsis.

New data from the AHA 2023 Statistical Update suggest more people died from cardiovascular-related causes in 2020 than in any year since 2003.

An analysis of the Jackson Heart Study reports economic food insecurity as a risk factor for incident CHD and incident HFrEF, independent of socioeconomic measures and traditional CV risk factors.

Rurality was associated with an increased risk of HF among women and Black men, which persisted after adjustment for cardiovascular risk factors and socioeconomic status.

Men in the highest quartile of PDE-5i exposure had the lowest incidence of MACE and overall mortality compared to the lowest exposure quartile.

In a cohort of consecutive HFrEF patients admitted with AHF, the findings suggest almost three-quarters of patients were eligible for combined quadruple therapy.

The COACH trial reported a hospital-based strategy led to lower risk of death from any cause or hospitalization for cardiovascular causes within 30 days than usual care in patients with acute heart failure.

Using real-world data from the US, Japan, and Sweden provides insight into contemporary trends in GDMT use, including initiation, uptitration, and discontinuation, following hospitalization among patients with heart failure with reduced ejection fraction.

With less than a week to go until the close of 2022, our editorial team is celebrating the final week of the year by recapping some of our most popular stories and content from the past year. Here, we are highlighting our most popular episodes of the Don’t Miss a Beat Podcast from 2022.

The advisory committee voted 3-8 against the benefit-risk profile of omecamtiv mecarbil for heart failure with reduced ejection fraction.

At AHA 2022, Dr. Ray discusses the findings from the phase II open-label extension trial and highlights other important trial data for lipidologists.

A deep dive into exciting late-breaking trial data at AHA 2022, differences in chest pain guidelines, and bringing patient voice into clinical research.

A Q&A with Dr. Bonaca highlights new data on rivaroxaban for PAD and the late-breaking science at AHA 2022.

In this episode of The Heart Team, which was recorded on-site at AHA 2022, Scott Solomon, MD, takes hosts Jorge Plutzky, MD, and Michael Farkouh, MD, on a deep dive into his experience as a trialist, use of newer medications, and what might be next for the heart failure community.

A substudy of the PRO-HF study indicates incorporation of KCCQ-12 scores was associated with an improved patient experience and a greater understanding of symptoms.

Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.

Data presented during ASN 2022 shows how heart failure impacts risk factors for renal outcomes of patients with chronic kidney disease.

AI-enabled retinal imaging can accurately predict CVD and death, without the need for blood tests or BP measurement, according to the findings.

Mobile health technology to detect AF led to a high rate of false positives in patients with certain cardiac conditions.

The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.

The observed reductions in CV mortality in patients treated with dapagliflozin were primarily due to lower rates of HF and sudden death.

An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.

A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.

Key opinion leaders in the cardiometabolic space describe the importance of the introduction of SGLT2 inhibitors for heart failure treatment based on 2022 guidelines.

SGLT2 inhibitors, ARNIs, and MRAs were associated with a significant decrease in hospital admission for heart failure.

This risk also increased with age and was amplified in patients with HCV compared to patients without HCV.

Dr. Thosani discusses the convergence of technology and physiology, treatment advancements, and virtual medicine capabilities in the field of heart arrhythmia.